Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Industry Funding Opportunities

This page contains information about current funding opportunities with Industry. If you are thinking of applying, please read all terms and conditions and feel free to get in touch with the named Oxford contact to talk more about the opportunity. Opportunities are not vetted at the stage of being included on this page. The page is updated on a monthly basis and is not exhaustive.

Provepharma life sciences - Seeking innovative research involving small molecule-peptide conjugates with therapeutic benefits  

 

Provepharm Life Solutions is an independent pharmaceutical group focused on the development of small molecule and peptide therapeutics for therapeutic applications. In this case, the company is seeking academic collaborators, research projects, or innovative technologies involving the conjugation of small molecules and peptides with the potential to be used as a therapeutic approach. These could include those focusing on optimising aspects relating to the conjugation of small molecules and peptides, or optimising one of these elements specifically to enhance the overall functionality of small molecule‑peptide conjugates. Peptides of all lengths and complexities are of interest. Potential applications of small molecule-peptide conjugates in all fields and disease areas will be considered, with examples including fluorescence‑guided surgery in the area of immuno‑oncology and immunotherapies more globally

Out of Scope: Cancer, Infectious diseases, Metabolic diseases, Central Nervous System Diseases, and Rare Diseases are out of scope for this campaign. All other diseases will be considered.

Deadline: Monday 3 August, 12am GMT

MSD Business Partnerships Office contact: siobhan.dennis@medsci.ox.ac.uk 

 

UK Functional Genomics Capability Build - Glaxosmithkline/oxford only call

GlaxoSmithKline (GSK) has issued a call for proposals for collaborative research in Functional Genomics (FxG) including Synthetic Lethality linked to GSK strategic priorities and leveraging key UK Life Sciences Infrastructure.

GSK logoGSK are seeking ambitious ideas that can transform their understanding of how genetics influences disease and enable the identification of novel and high quality genetically validated targets. This call aims to enable GSK to build relationships and capability in this area with a view to determining where to focus their UK FxG investments in the longer term.

Deadline: 28th August 2020

Full details: https://www.medsci.ox.ac.uk/research/internal/funding-directory/uk-functional-genomics-capability-build

MSD Business Partnerships Office contact: charlotte.bell@medsci.ox.ac.uk 

MERCK 2020 RESEARCH GRANTS

A series of research grants to stimulate innovative research in challenging areas of future importance. Grants of 100,000 EUR - 500,000 EUR per year for up to 3 years are available in the areas of: 

  • Drug discovery
  • Next generation machine learning
  • Pandemic preparedness / fighting new emerging viral infectious diseases
  • Bioreactor design for cultured meat

Deadline: Monday 31 August 2020, 23:59 CEST

Full details: https://www.merckgroup.com/en/research/open-innovation/2020-research-grants.html

MSD Business Partnerships Office contact: charlotte.bell@medsci.ox.ac.uk 

 

  

MERCK 2020 RESEARCH CHALLENGES 

A series of research competitions for technology pioneers in areas of high innovation:

  • compound synthesis
  • high-k dielectric materials
  • publication impact
  • laboratory connectivity

Deadline: Various

Full details: https://www.merckgroup.com/en/research/open-innovation/2020-research-challenges.html

Translational Research Office Contact: anne-sophie.schillinger@medsci.ox.ac.uk

 

 

Pfizer Centers for Therapeutic Innovation call for proposals 2020

Pfizer pre-clinical collaborating core research focus areas: oncology, inflammation & immunology, internal medicine and rare diseases.

Non-confidential pre-proposals will be reviewed on a rolling basis from 1 June –  28 September.

Opportunities related to DNA Damage Response and Replicative Stress such as:

  • Chromatin and DNA damage response modulators in the context of nuclear or spatial organization (e.g. biochemical condensates)
  • Novel targets identified via synthetic lethal, chemical biology or other approaches, including DNA repair enzymes (esp. nucleases), scaffolding factors and nucleic acid targets (R-loops, G-quadruplexes)
  • DNA damage proteins associated with diseases such as cancer and repeat expansion diseases

Out-of-scope: cell therapies, antibody-drug conjugates, nucleic acid therapeutics

 

Opportunities that address the cause or treatment of Repeat Expansion Diseases, such as:

  • Therapeutic targeting of the mutant gene
  • Interventions that halt or reverse the somatic expansion of the repeating DNA sequences
  • Novel mechanisms that modulate or regulate the pathological repeat
  • Genetic modifiers of repeat instability or repeat contraction

Out-of-scope: therapeutic approaches that target/clear protein aggregates

Opportunities to target Cellular Senescence, including senolytic and senomomorphic approaches such as:

  • Induction or targeting of senescent-like arrest of tumor cells to overcome drug resistance and/or improve immune response to solid tumors
  • Novel senescence targets related to fibrosis, specifically mechanisms responsible for modulating fibroblasts/myofibroblasts function and tissue remodeling by stem/tissue progenitor cells
  • Targeting of senescence pathways in tissue resident immune cells in the liver, lung, skin, joints, and gastrointestinal tract that contribute to disease

Out-of-scope: telomeres/telomerase targeting approaches, age-related dysfunction

Opportunities related to Tissue-Immune System Crosstalk in disease pathology including:

  • Targets/pathways that induce immune tolerance by modulation of unique or accessory regulatory cells including macrophages (Mregs), B cells (Bregs), and tolerogenic dendritic cells (tolDCs)
  • Novel inflammatory pathways/targets in tissue-resident innate, parenchymal, and stromal cell populations including fibroblasts, stem/tissue progenitors, neutrophils and macrophages

Out-of-scope: cell and gene therapies

Rolling deadline until Monday 28 September 2020

MSD Business Partnerships Office contact: martin.kerr@medsci.ox.ac.uk 

On this page